Expansion offers the potential for continuous, discreet and simplified epidural glucose monitoring solutions for patients with Painful Diabetic Neuropathy

扩展为患有疼痛性糖尿病神经病变的患者提供了连续，谨慎和简化的硬膜外葡萄糖监测解决方案的潜力

Rutherford, NJ, April 16, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it is expanding its glucose monitoring technology to include measuring glucose in the epidural space.

新泽西州卢瑟福，2024年4月16日（环球通讯社）--Glucotrack，Inc.（纳斯达克：GCTK）（“Glucotrack”或“公司”）是一家专注于糖尿病患者新技术的设计、开发和商业化的医疗器械公司，宣布将其葡萄糖监测技术扩展到包括测量硬膜外间隙的葡萄糖。

A continuous glucose monitoring system that takes readings in the spinal epidural space may be integrated with existing treatments for patients with Painful Diabetic Neuropathy (PDN)..

连续血糖监测系统可以在脊髓硬膜外腔读取读数，可以与现有的治疗疼痛性糖尿病神经病变（PDN）患者的治疗相结合。。

PDN is a progressive neurological disorder that affects approximately one-fifth of the more than 38 million Americans with with diabetes, equating to more than 7 million individuals.1,2 Its symptoms include pain and numbness in the feet, legs, and hands which can significantly impact patients’ quality of life and functional ability.3 Recently, Spinal Cord Stimulation (SCS) technology has been indicated as a treatment option providing significant long-term pain relief to these patients.4 A spinal cord stimulator is an implanted device, with electrodes placed in the epidural space, that sends low levels of electricity directly into the spinal cord to relieve pain.5 Glucotrack’s sensor has the potential to be integrated with existing SCS devices to measure epidural glucose in patients with PDN who are undergoing SCS treatment.

PDN是一种进行性神经系统疾病，在3800多万美国糖尿病患者中，约有五分之一受到影响，相当于700多万人。1,2其症状包括脚、腿和手的疼痛和麻木，可显着影响患者的生活质量和功能能力。3最近，脊髓刺激（SCS）技术已被证明是一种治疗选择，可为这些患者提供显着的长期疼痛缓解。4脊髓刺激器是一种植入装置，电极置于硬膜外腔，可将低水平的电直接发送到脊髓以缓解疼痛。5 Glucotrack的传感器有可能与现有的SCS装置集成，以测量硬膜外患者的血糖正在接受SCS治疗的PDN。

Combining SCS and continuous glucose monitoring (CGM) could provide several possible advantages, such as simplifying device management for those patients..

将SCS和连续血糖监测（CGM）相结合可以提供几个可能的优势，例如简化这些患者的设备管理。。

Glucotrack has successfully completed preclinical animal testing in an acute setting. Building on the success of the acute studies, the Company has now initiated a long-term animal study to assess sustained epidural glucose monitoring performance. This is the second application of Glucotrack’s technology for implantable continuous glucose monitoring, in addition to its development of a long-term Continuous Blood Glucose Monitoring (CBGM) system..

Glucotrack已在急性环境中成功完成临床前动物测试。在急性研究成功的基础上，该公司现在开始了一项长期动物研究，以评估持续的硬膜外血糖监测性能。这是Glucotrack技术在植入式连续血糖监测中的第二次应用，此外还开发了长期连续血糖监测（CBGM）系统。。

The preclinical testing compared the Glucotrack sensor against blood glucose and a commercially available subcutaneous CGM in an acute large animal model while varying blood glucose levels for several hours. The results demonstrated the Glucotrack epidural glucose values closely tracked both the blood glucose and subcutaneous CGM values.

临床前测试比较了Glucotrack传感器与急性大型动物模型中的血糖和市售皮下CGM，同时改变血糖水平数小时。结果表明，Glucotrack硬膜外葡萄糖值与血糖和皮下CGM值密切相关。

The study was completed with no adverse effect on the animals. A second acute study successfully confirmed the repeatability of these results..

该研究已完成，对动物没有不良影响。第二项急性研究成功证实了这些结果的可重复性。。

“We have always been committed to developing a portfolio of innovative glucose monitoring technologies to offer patients with diabetes more choice; today’s announcement underscores this commitment.” said Paul V. Goode, PhD, CEO of Glucotrack. “We are excited to pioneer the epidural glucose monitoring space which we believe holds meaningful strategic potential.

Glucotrack首席执行官Paul V.Goode博士说：“我们一直致力于开发一系列创新的血糖监测技术，为糖尿病患者提供更多的选择；今天的公告强调了这一承诺。”。“我们很高兴能开创硬膜外血糖监测领域，我们认为这具有重要的战略潜力。

By making disease management more intuitive and less intrusive, Glucotrack is looking beyond traditional approaches to improve the quality of life for millions of people with diabetes.”.

通过使疾病管理更直观，更少干扰，Glucotrack正在超越传统方法，改善数百万糖尿病患者的生活质量。”。

For more information about Glucotrack, visit glucotrack.com.

有关Glucotrack的更多信息，请访问Glucotrack.com。

# # #

# # #

About Glucotrack, Inc.

关于Glucotrac，股份有限公司。

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.

Glucotrack，Inc.（纳斯达克：GCTK）专注于为糖尿病患者设计、开发和商业化新技术。该公司目前正在为糖尿病患者开发一种长期植入式连续血糖监测系统。

Glucotrack’s CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 2+ years, no on-body wearable component and with minimal calibration. For more information, please visit http://www.glucotrack.com.

Glucotrack的CBGM是一种长期植入式系统，可连续测量血糖水平，传感器寿命为2年以上，无体内可穿戴组件，校准最少。有关更多信息，请访问http://www.glucotrack.com.

Forward-Looking Statements

前瞻性声明

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements.

本新闻稿包含1995年《私人证券诉讼改革法案》所指的前瞻性声明。本新闻稿中包含的非历史事实声明可能被视为前瞻性声明。在不限制上述一般性的情况下，诸如“相信”、“期望”、“计划”和“将”等词语旨在识别前瞻性陈述。

Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

此类前瞻性陈述基于管理层的信念，以及管理层做出的假设和目前可获得的信息。这些声明仅涉及截至声明发布之日的事件，Glucotrack没有义务公开更新任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。

All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by the Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations.

本新闻稿中的所有前瞻性声明均由这些警告性声明限定，无法保证Glucotrack预期的实际结果会实现，或者即使基本实现，也无法保证它们会对我们或我们的业务或运营产生预期的后果或影响。

Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including U.S.

读者应注意，某些重要因素可能会影响Glucotrack的实际结果，并可能导致这些结果与本新闻稿中可能发表的任何前瞻性声明存在重大差异。可能影响Glucotrack业绩的因素包括但不限于Glucotrack筹集额外资本以资助其运营的能力（无论是通过公开或私人股本发行、债务融资、战略合作还是其他方式）；与监管批准的接收（和时间安排）相关的风险（包括美国。

Food and Drug Administration approval).

食品和药物管理局批准）。

Contacts:

联系人：

Investor Relations:

投资者关系：

investors@glucotrack.com

investors@glucotrack.com

Media:

媒体：

GlucotrackPR@icrinc.com

GlucotrackPR@icrinc.com

References:

参考文献：

1 Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011;34:2220–2224.

1雅培CA，马利克RA，范·罗斯ER，库尔卡尼J，博尔顿AJ。英国糖尿病护理2011年大型社区糖尿病人群疼痛性糖尿病神经病变的患病率和特征；34:2220-2224。

2 Centers for Disease Control and Prevention. (2022). National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html

2个疾病控制和预防中心。（2022年）。国家糖尿病统计报告网站。https://www.cdc.gov/diabetes/data/statistics-report/index.html

3 Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18(6):350-354. doi:10.1097/00002508-200211000-00002.

3 Schmader KE。带状疱疹后神经痛和疼痛性糖尿病神经病变的流行病学及其对生活质量的影响。临床J疼痛。2002年；18（6）：350-354。内政部：10.1097/00002508-200211000-00002。

4 Erika A. Petersen, Thomas G. Stauss, James A. Scowcroft, Elizabeth S. Brooks, Judith L. White, Shawn M. Sills, Kasra Amirdelfan, Maged N. Guirguis, Jijun Xu, Cong Yu, Ali Nairizi, Denis G. Patterson, Kostandinos C. Tsoulfas, Michael J. Creamer, Vincent Galan, Richard H. Bundschu, Neel D. Mehta, Dawood Sayed, Shivanand P.

4埃里卡·彼得森（Erika A.Petersen）、托马斯·施特劳斯（Thomas G.Stauss）、詹姆斯·斯考克罗夫特（James A.Scowcroft）、伊丽莎白·S·布鲁克斯（Elizabeth S.Brooks）、朱迪思·L·怀特（Judith L.White）、肖恩·M·西尔斯（Shawn M.Sills）、卡斯拉·阿米尔德凡（Kasra Amirdelfan）、马吉德·N·吉尔吉斯（Maged N.Guirguis）、徐吉军（Jijun Xu）、丛余（Cong Yu）、阿里·奈里兹（Ali Nairizi）、丹尼斯·G.帕特森（De。

Lad, David J. DiBenedetto, Khalid A. Sethi, Johnathan H. Goree, Matthew T. Bennett, Nathan J. Harrison, Atef F. Israel, Paul Chang, Paul W. Wu, Charles E. Argoff, Christian E. Nasr, Rod S. Taylor, David L. Caraway, Nagy A. Mekhail; Durability of High-Frequency 10-kHz Spinal Cord Stimulation for Patients With Painful Diabetic Neuropathy Refractory to Conventional Treatments: 12-Month Results From a Randomized Controlled Trial.

Lad，David J.DiBenedetto，Khalid A.Sethi，Johnathan H.Goree，Matthew T.Bennett，Nathan J.Harrison，Atef F.Israel，Paul Chang，Paul W.Wu，Charles E.Argoff，Christian E.Nasr，Rod S.Taylor，David L.Caraway，Nagy A.Mekhail；高频10 kHz脊髓刺激对常规治疗难治性疼痛性糖尿病神经病变患者的持久性：一项随机对照试验的12个月结果。

Diabetes Care 5 January 2022; 45 (1): e3–e6. https://doi.org/10.2337/dc21-1813.

糖尿病护理2022年1月5日；45（1）：e3–e6。https://doi.org/10.2337/dc21-1813.

5 Dydyk AM, Tadi P. Spinal Cord Stimulator Implant. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK555994/

5 Dydyk AM，Tadi P.脊髓刺激器植入物。[于2023年7月3日更新]。在：StatPearls[互联网]。金银岛（佛罗里达）：StatPearls出版社；2024年1月-。可从以下地址获得：https://www.ncbi.nlm.nih.gov/books/NBK555994/